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ABSTRACT. Since the first report of the enhanced permeability and retention (EPR) effect, the 
research in nanocarrier based anti-tumor drugs has been intense. The field has been devoted to 
treatment of cancer by exploiting EPR-based accumulation of nanocarriers in solid tumors, which 
for many years was considered to be a ubiquitous phenomenon. However, the understanding of 
differences in the EPR-effect between tumor types, heterogeneities within each patient group, and 
dependency on tumor development stage in humans is sparse. It is therefore important to enhance 
our understanding of the EPR-effect in large animals and humans with spontaneously developed 
cancer. In the present paper, we describe a novel loading method of copper-64 into PEGylated 
liposomes and use these liposomes to evaluate the EPR-effect in 11 canine cancer patients with 
spontaneous solid tumors by PET/CT imaging. We thereby provide the first high-resolution analysis 
of EPR-based tumor accumulation in large animals. We find that the EPR-effect is strong in some 
tumor types but cannot be considered a general feature of solid malignant tumors since we observed 
a high degree of accumulation heterogeneity between tumors. Six of seven included carcinomas 
displayed high uptake levels of liposomes, whereas one of four sarcomas displayed signs of 
liposome retention. We conclude that nanocarrier-radiotracers could be important in identifying 
cancer patients that will benefit from nanocarrier-based therapeutics in clinical practice. 
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The therapeutic potential of nanocarrier based chemotherapeutics for the treatment of cancer is 
considered huge and considerable success has been achieved since its introduction.1,2 Many of the 
developed nanocarrier systems are considered to accumulate in tumors based on the enhanced 
permeability and retention (EPR)-effect,3 which in nanomedicine research has been considered a 
universal feature of solid malignant tumors that can serve as the basis for passive tumor targeting of 
therapeutic and diagnostic nanoparticles.4-6  
Solid tumors growing beyond a size of a few millimeters depend on successful formation of neo-
angiogenic blood vessels to meet their oxygen and energy requirements, and for removal of waste 
products.7,8 The blood vessels of malignant tumors display several anatomical and patho-
physiological differences relative to the vessels in normal tissues. Tumors display a poorly 
organized vascular architecture, which have been reported to include wide endothelial fenestrations 
and absent lymphatic drainage.5,9,10 These features form the basis for the EPR-based extravasation of 
nano-sized particles into tumor tissue.5,9 The heterogeneous tumor microenvironment contains well-
characterized loco-regional features that may affect the accumulation of nanoparticles in tumors, 
including poorly perfused regions of hypoxia11 and regional activity of vasoactive proteins.12,13  
Massive efforts are currently directed towards the development of nanocarriers that can deliver 
drugs to cellular and subcellular targets in tumors. It has been argued that the therapeutic benefit of 
marketed nanotherapeutics for cancer relates to reduced toxicity, e.g. reduced cardiovascular 
toxicity of Doxil relative to doxorubicin rather than an improved therapeutic effect.14 To provide 
new evidence of the therapeutic potential of nanocarrier systems for treating cancer, an important 
question to address is related to the EPR-effect. Current knowledge on the ability of nanocarriers to 
deliver chemotherapeutics to solid tumors mainly originates from quantitative estimation of tumor 
targeting in experimental models, primarily xenografts in mice, and the actual data in cancer 
patients is scarce. It is remarkable that despite the theoretical potential and obtained results, only 
limited efforts have been made to investigate tumor targeting of nanoparticle formulations in 
spontaneous tumors in large animals. Current knowledge on the EPR-effect in human tumors is 
based on studies of low-resolution single photon imaging techniques of radiolabeled liposomes.15-18 
Liposome uptake has been investigated in a Kaposi sarcoma and a lymphoma patient.16 
Furthermore, targeting and delineation has been investigated in eight high-grade gliomas17 and 
positive tumor identification using radiolabeled phospholipid vesicles in 22 of 24 patients suffering 
from a few malignancies.18 Gamma camera and single-photon emission computed tomography 
(SPECT) imaging of 111In-DTPA-labeled pegylated liposomes was also performed in 17 patients 
suffering from head and neck, breast, bronchus and cervix cancer and two glioma patients, with 12 
tumors being identified by gamma camera imaging and 15 tumors identified by SPECT.15 However, 
all these studies only provide the conclusion that tumors were visible due to presence of 
radiolabeled liposomes in the tumor and did not report direct quantitative evidence of the EPR-
effect, as we will show and discuss in the present study. Thus, there is a strong need for studies in 
large animals with spontaneous syngeneic tumors, with a microenvironment and vasculature that is 
comparable to human tumors, as this will elucidate the tumor targeting potential of nanocarriers and 
thereby guide future development of nanoparticle-based drug delivery systems.  
In this study, we report a new and highly efficient method for labeling PEGylated liposomes 
with copper-64 and utilize positron emission tomography/computed tomography (PET/CT) imaging 
to evaluate liposome tumor accumulation including heterogeneity and pharmacokinetics in family 
owned dogs with spontaneous solid tumors.  The new loading method is based on an un-assisted 
transport of copper-64 into liposomes, which is surprisingly efficient as diffusion of divalent cations 
such as Cu2+ across lipid bilayers is highly un-expected. We utilize the developed copper-64 
liposome imaging agents for studying the EPR-effect in dogs with cancer as the biological features 
of cancer in dogs is similar to humans and their size and heterogeneous microenvironment make 
them attractive models for comparative research.19 PEGylated liposomes with the same lipid 
composition as the clinically used Doxil formulation, radiolabeled with copper-64 ([Cu-64]-
liposomes), were utilized in the study. PET/CT imaging allows for the acquisition of dynamic 
imaging data and determination of direct quantitative uptake data within specific regions of interest 
(ROI).20,21 The high detection sensitivity and spatial resolution of PET compared to SPECT and 
sensitivity compared to magnetic resonance (MR) imaging makes PET superior for quantitative 
studies of nanoparticle biodistribution.20,22,23 In addition, PET is a true quantitative technique. 
 
Results  
Preparation of liposome imaging probes by un-assisted loading of Copper-64. In the present 
work, DSPC:CHOL:DSPE-PEG2000 (56.5:38.2:5.3) liposomes were prepared with the high affinity 
copper chelator DOTA encapsulated. These liposomes were used for loading of [Cu-64]2+ by a new 
un-assisted loading method without the use of ionophores or ion transporters,24 as schematically 
illustrated in Figure 1a. In this method, copper-64 chloride is added to liposome solutions and post-
loading purification is not needed due to very high loading efficiencies, which is important for PET 
imaging due to the short half-life of PET isotopes (e.g. copper-64 has a 12.7 h half-life). Un-
assisted loading of [Cu-64]2+ into the liposomes was possible by increasing the temperature during 
loading to 55 °C, which was surprising as divalent cations are not generally expected to cross lipid 
bilayers.24 The [Cu-64]2+ was trapped inside the liposome by the encapsulated DOTA. Liposome 
loading kinetics of [Cu-64]2+ was evaluated using radio-TLC (Figure 1b) and size exclusion 
chromatography. Full loading was observed at 55 °C within 60 min after addition of 64-copper 
chloride, where >98% of the copper was loaded in 10 independent experiments. The [Cu-64]2+  
loading was surprisingly fast where 38% ± 3% was loaded within the first minute after addition. 
The [Cu-64]-liposomes was used without further purification in the dog study, which was possible 
due to the very high loading efficiency.  
 
Figure 1. (a) Schematic illustration of Loading of [Cu-64]2+  into liposomes. After addition of [Cu-
64]2+ to a liposome solution, [Cu-64]2+ diffuse across the lipid bilayer without the use of ionophores 
or ion-transporters. [Cu-64]2+ then forms a complex with the encapsulated chelator (DOTA) and is 
hereby trapped inside the liposome. (b) Loading efficiency of liposomes given as function of time. 
The loading efficiency, for loading of [Cu-64]2+ into liposomes, was evaluated at 55 °C by the use 
of radio-TLC at 1, 3, 8, 15, 30 and 60 min. The liposomes were composed of HSPC:CHOL:DSPE-
PEG2000 in the molar ratio (56.5:38.2:5.3). The error bars represent SEM (n = 3). 
 
 
EPR based liposomal accumulation in spontaneous tumors in canine patients. Family 
owned dogs suffering from spontaneous malignancies were included in the study. All dogs had a 
histopathological diagnosis based on tumor formalin fixed paraffin embedded HE stained tumor 
biopsies or sections. [Cu-64]-liposomes with a composition of HSPC/Cholesterol/DSPE-PEG2000 
56.5:38.2:5.3 were used (Doxil lipid composition), which allowed for high-resolution PET imaging 
of liposome biodistribution. Six of the included 11 dogs were also subjected to 2-[18F]fluoro-2-
deoxy-D-glucose (FDG) PET/CT imaging. FDG PET/CT has a central position for PET imaging of 
cancer patients and was performed for tumor delineation and staging purposes.  
The first [Cu-64]-liposome PET/CT scan was recorded one day after the FDG PET/CT. Dogs 
had PET/CT scans performed on two consecutive days approximately 24 h apart, except for dog 11 
where the 1-hour [Cu-64]-liposome PET/CT was not performed for technical reasons. The [Cu-64]-
liposomes were administered by intravenous infusion at increasing rates over a 20 min period. None 
of the included dogs displayed any anaphylactic, toxic or adverse reactions. Tumor characteristics 
and PET uptake of FDG and [Cu-64]-liposomes (standardized uptake value (SUV)) are reported in 
Table 1. [Cu-64]-liposome PET scans were performed dynamically during the initial 0-40 min over 
the liver and spleen, and hereafter 40-60 min over the tumor (termed 1-hour scan), and again after 
24 h (termed 24-hour scan). The FDG scanned carcinomas displayed higher SUV of FDG relative 
to the sarcomas, which is in agreement with a previous report on FDG PET in dogs.25 All 
carcinomas displayed increased mean SUV (SUVmean) and particularly maximum SUV (SUVmax) of 
[Cu-64]-liposomes between the 1-hour and 24-hour PET scans, except dog 9 where SUVmean did not 
increase between scans. Oppositely, SUV did not increase for the sarcomas, except for a SUVmax 
increase in dog 4.  
 
Table 1. Dog and tumor characteristics, and tumor uptake as standardized uptake values (SUV) for 18FDG 
and [Cu-64]-liposomes 
 
 
Dog 
 
 
Age/ 
 
 
Breed 
 
 
BW 
(kg) 
 
 
Tumor 
type 
 
 
Tumor 
volume 
(cm3) 
 
 
Tumor  
location 
 
18FDG 
PET/CT 
1-hour 
[64-Cu]-liposome 
PET/CT 
24-hour 
[64-Cu]-liposome 
PET/CT 
Sex  SUVmean SUVmax SUVmean SUVmax SUVmean SUVmax 
1 11/M Golden 
Retriever 
39 SCC 4.0 Intranasal 8.7 14.5 2.1 5.5 6.1 21.3 
2 8/F Mixed 
breed 
28 AC 274.5 Mammary  
glands 
4.8 17.6 0.7 3.2 1.3 11.2 
3 5/F Labrador 
Retriever 
25 AC 19.4 Sub-
mandibular 
5.3 8.4 1.3 4.2 1.6 7.7 
4 8/F Beagle 12 STS 32.6 Masticatory 
muscle 
1.8 4.3 0.5 2.0 0.4 2.6 
5 5/M Münster-
länder 
25 STS 10.5 Neck  
muscle 
2.0 4.7 0.6 2.3 0.4 1.4 
6 6/F Labrador 
Retriever 
32 LS 4.8 Ante-
brachium 
2.4 3.6 0.8 2.5 0.6 1.5 
7 
 
12/M Labrador 
Retriever 
33 TCC 22.0 Intranasal - - 1.4 3.7 2.6 18.7 
8 
 
7/F Labrador 
Retriever 
27 STS 10.1 Front paw - - 0.6 1.6 0.3 1.4 
9 
 
9/F Dachshund 10 AC 7.1 Mammary  
glands 
- - 0.7 1.7 0.7 2.0 
10 
 
10/M Schnauzer 13 SCC 8.0 Intranasal - - 1.3 4.7 2.9 6.9 
11 12/M Golden 
Retriever 
32 AC 36.6 Intranasal - - - - 1.6 10.2 
M: Male, F: Female, BW: Bodyweight, SCC: Squamous cell carcinoma, AC: Adenocarcinoma, STS: Soft tissue sarcoma, TCC: 
Transitional cell carcinoma, LS: Liposarcoma. Carcinomas in bold. Tumor volume determined by PET/CT-scan. 
 
 
Figure 2. FDG PET/CT and [Cu-64]-liposome PET/CT. PET/CT image of the intranasal squamous cell 
carcinoma in the right nasal cavity of dog 1 (a-c), illustrating tumor accumulation of FDG (a), [Cu-64]-
liposome PET/CT 1 h after liposome infusion (b), [Cu-64]-liposome PET/CT 24 h after liposome infusion 
(c). The heterogeneous tumor uptake of the liposomes (24-hour PET/CT) can be visually appreciated on the 
24-hour [Cu-64]-liposome PET/CT image of the adenocarcinoma of dog 3 (d). 24-hour [Cu-64]-liposome 
PET/CT images of the soft tissue sarcomas (STS) in the mandibular region of dog 4 (e) and the neck 
musculature of dog 5 (f) illustrates the low accumulation in these tumors relative the carcinomas (c,d). 
Tumors are marked by arrows or delineated by white lines and larger blood vessels by red circles (c-d). 
 
Accumulation levels of [Cu-64]-liposomes were determined by calculating decay corrected 
percentage of injected dose (%ID) of [Cu-64]-liposomes in tumors (Table 2). The included 
carcinomas displayed increased total tumor, mean and maximum %ID of [Cu-64]-liposomes 
between the 1-hour and 24-hour PET scans, except dog 9 where a slightly decreased mean and total 
%ID/g was observed. The included sarcomas displayed decreased %ID values, except for a slightly 
increased maximum %ID in dog 4. The tumor mean %ID/kg after a distribution period of only 1 h 
is expected to primarily consist of activity in tumor vasculature and ranged from 2.2 – 11.2 (mean 
4.5, SEM 0.8) %ID/kg.  
 
Table 2. Tumor uptake levels of [Cu-64]-liposomes 1 and 24 hours after injection	
 
 
 
Dog 
1-hour 
[Cu-64]-liposome PET/CT 
 24-hour 
[Cu-64]-liposome PET/CT 
Total 
%ID 
Mean 
%ID/kg 
Max 
%ID/kg 
 Total 
%ID 
Mean 
%ID/kg 
Max 
%ID/kg 
1 0.02 4.6 16  0.07 17 59 
2 0.61 2.5 11  1.29 4.8 40 
3 0.11 5.2 17  0.13 6.5 31 
4 0.14 3.8 15  0.11 3.5 21 
5 0.03 2.5 7.7  0.02 1.5 5.7 
6 0.01 2.3 7.9  0.01 1.8 4.7 
7 0.10 4.2 11.2  0.18 8.1 57.1 
8 0.03 2.2 6.1  0.01 1.1 5.3 
9 0.09 7.4 17  0.05 6.7 20.0 
10 0.10 11.2 35.8  0.19 23.1 54.1 
11 - - -  0.20 5.4 32.0 
Total %ID: Percentage of injected dose in total. Mean and max %ID/kg: Mean and maximum percentage of injected dose pr. kg of 
tumor tissue determined from liposome PET/CT scans performed 1 h and 24 h after injection. Carcinomas in bold.  
 
Visual evaluation of the PET/CT images clearly illustrated the differences between the included 
carcinomas and sarcomas. [Cu-64]-liposome PET/CT clearly delineated all carcinomas, except the 
mammary adenocarcinoma of dog 9, but none of the sarcomas after 24 h (Figure 2a-f).  Importantly, 
the observed heterogeneity in tumor voxel uptake levels could be visually appreciated even in 
tumors displaying avid accumulation of [Cu-64]-liposomes (Figure 2c-d). PET/CT images of all 11 
dogs are shown in Supplementary Figure S1 and S2. The observed difference in accumulation 
levels of [Cu-64]-liposomes between carcinomas and sarcomas are illustrated by the tumor 
maximum to blood mean and tumor mean to blood mean ratios, as well as tumor to liver and muscle 
ratios (Figure 3). The tumor-to-reference tissue ratios identify differences between tumors and 
underline the variation in tumor targeting potential of liposomal systems for different malignancies. 
The tumor-to-blood ratios between the 1-hour and 24-hour time point gives information about the 
extravasation of liposomes into tumor tissue. Most noteworthy is that we observe an increase in the 
tumor max to blood mean ratio between the 1-hour and 24-hour scans in all except one of the 
carcinomas but only see such an increase in one of the sarcomas (Figure 3a). Also, we only observe 
a very high increase in tumor mean to blood mean ratio in 2 of the dogs investigated (Figure 3b), 
which underlines the heterogeneity in the EPR-effect in the investigated tumor types. 
	  
Figure 3. Tumor-to-reference tissue activity ratios. Tumor maximum to blood mean (Tmax/Bmean) and tumor 
mean to blood mean (Tmean/Bmean) activity ratios on the 1-hour and 24-hour PET scans (a and b) and tumor 
maximum to liver mean (Tmax/Lmean) and tumor mean activity to liver mean (Tmean/Lmean) (c) and muscle mean 
(Mmean) (d) activity ratios at the 24-hour PET scan. Carcinomas (☐) and sarcomas (l). 
 
We generated histograms of voxel %ID/kg to provide an analysis of the voxel activity 
distribution (Supplementary Figure S3). From the histograms the heterogeneity in [Cu-64]-
liposome activity can be readily appreciated for all tumors. In order to obtain acceptable lesion 
identification a lesion to background ratio (e.g. tumor-to-muscle ratio) above 1.5 is generally 
required.26 All of the included tumors displayed a Tmax/Mmean ratio above 1.5. However, for the 
sarcomas less than 30% of tumor voxels displayed an acceptable ratio whereas the majority of 
voxels displayed a Tvoxel/Mmean ratio above 1.5 for the included carcinomas, except dog 9 
(Supplementary Figure S4).  
We identified multiple pulmonary and lymph node metastases on the FDG PET/CT scans from 
dog 2 and these displayed [Cu-64]-liposome activity (Figure 4a-b). The lymph node metastases 
were confirmed by cytology. FDG uptake was observed in the metastatic lesions (mean SUV 3.5 – 
6.8 and maximum SUV 5.3 – 16.7). Mean 24-hour [Cu-64]-liposome SUV for metastatic lesions 
ranged from 0.9 – 2.1 and maximum SUV from 1.3 – 7.9. These observations suggest that the EPR-
effect may also exist in metastases originating from primary EPR-positive tumors, thus suggesting 
that at least some macroscopic metastases will benefit from nanocarrier based drug delivery 
systems. No metastases were identified in any of the remaining dogs.  
 
 
Figure 4. Transversal, coronal and sagittal [Cu-64]-liposome PET/CT images after a distribution period of 
24 h in dog 2. (a) Transversal PET/CT image, [Cu-64]-liposome uptake can be appreciated in the axillary 
lymph node (arrows) and in the larger centrally located blood vessels, (b) transversal PET/CT image, [Cu-
64]-liposome uptake can be appreciated in the tumor (arrows), larger blood vessels and in the spleen located 
above the tumor. The high [Cu-64]-liposome activity levels in the blood can be appreciated in the heart 
ventricles, larger blood vessels, liver and spleen visualized in the coronal plane (c) and sagittal plane (d). 
Brain (yellow arrow), heart displaying the difference between blood activity in heart chambers and heart 
musculature (red arrow), liver (white arrow), where the circular gall bladder can be appreciated as a circular 
structure within the liver without any noteworthy [Cu-64]-liposome uptake, spleen (blue arrow) and urinary 
bladder (green arrow).  
 
Kinetics and biodistribution. We derived time activity curves (TAC) for blood, liver and spleen 
from the dynamic PET scan acquired during the initial 40 min of liposome distribution (including 
the infusion period), reconstructed at 1-minute intervals, and from the 24-hour PET scan (Figure 
5a). The %ID/cm3 increases in the blood during the 20-minute infusion period and decreases to 
reach a mean of 0.039 %ID/cm3 (SEM 0.014) after a distribution period of 24 h (Figure 5a-b). The 
%ID/cm3 in the liver and spleen increased during the infusion and reached mean uptakes of 0.025 
ID%/cm3 (SEM 0.007) and 0.014 ID%/cm3 (SEM 0.005) after 24 h. Considering the blood volume 
in liver and spleen, the non-blood associated [Cu-64]-liposome activity in these organs increases 
over the 24 h period. This indicates that the PEGylated liposomes undergo the expected elimination 
by the reticuloendothelial system. We observed no signs of liposome leakage of Cu-DOTA on the 
PET images, i.e. we observed no increase in activity in the urinary bladder, we observed normal 
spleen or liver uptake (the standard liposome clearance organs) and the PET image analysis 
conveyed what could be expected for long-circulating liposomes. Comparison of [Cu-64]-
liposomes, free [Cu-64]-DOTA and free [Cu-64(aq)] was performed in mice to determine 
differences in biodistribution and accumulation kinetics (Supplementary Figure S5). Kinetics and 
biodistribution of the three [Cu-64] compositions indicate that [Cu-64]-liposomes are stable in 
dogs, i.e. no indication of leakage of [Cu-64]-DOTA was observed. Additionally, a study where 
[Cu-64]-liposomes were incubated in canine plasma revealed that the stability of [Cu-64]-liposomes 
was very high with <3% leakage of [Cu-64]-DOTA (Supplementary Figure S6).   	
 
Figure 5. [Cu-64]-liposome distribution and circulating properties. (a) Percentage of injected dose (%ID) of 
[Cu-64]-liposomes pr. cm3 of blood, liver and spleen plotted against distribution time for the initial 40 min 
and after approximately 24 h (mean ± SEM). (b) Time activity curves (TAC) of fraction of injected activity 
of [Cu-64]-liposomes in blood circulation at various distribution time points. Fraction of injected activity is 
based on a calculated blood volume of 8% of total bodyweight (mean ± SEM). (c) Biodistribution of [Cu-
64]-liposomes after a distribution period of approximately 24 h (standardized uptake value (SUV) mean ± 
SEM).  
 
TACs of decay corrected percentage of [Cu-64]-liposome in circulation were calculated from 
triplicates of well-counted blood samples (Figure 5b). Circulating half-life was estimated to 35.0 h 
(SEM 4.2 h), based on non-linear one-phase exponential decay. Goodness-of-fit (R2) ranged from 
0.80 – 0.92 indicating an acceptable curve fit. The estimated circulating half-life is comparable to 
those reported in humans for pegylated liposomal doxorubicin (Doxil™) and [In-111]-labeled 
pegylated liposomes.15,27 The circulating half-life of the liposome formulation could be appreciated 
on the 24-hour PET/CT images (Figure 4). 
Biodistribution in selected tissues and organs was determined from the 24-hour [Cu-64]-
liposome PET scans (Figure 5c). High activity of [Cu-64]-liposomes was observed in the aorta, 
liver, spleen and renal cortices, whereas the lowest activity was observed in bone marrow (proximal 
humerus), lung, muscle, brain and parotid glands.  
 
Discussion 
In the present study we have developed a new method for preparing PET radionuclide [Cu-64]2+ 
labelled liposomes that can easily be used by for radiolabeling liposomes in both preclinical and 
clinical settings. The highly efficient and fast loading procedure that was developed, where [Cu-
64]2+ is efficiently diffusing across the liposome membrane at elevated temperature was a surprise 
to us and we tested loading of Ca2+ to investigate if this was a general phenomenon. Ca2+ was not 
able to diffuse across the liposome membrane and it seems that there are differences in the 
membrane interactions of Cu2+ and Ca2+. The exact mechanism that is causing this difference is 
unknown to us and we were highly surprised that we can load  [Cu-64]2+ so effectively into 
liposomes by using a chemical gradient constituted by the DOTA chelate. We will in future studies 
further investigate this phenomenon. This study furthermore represents the first PET/CT study of a 
radiolabeled nanocarrier in a clinical animal model with spontaneous tumors. The PET/CT imaging 
provided high-resolution and quantitative data on liposome tumor accumulation in dogs with 
cancer, which are comparable to human cancers. Thus, the study provides unique new information 
that should be evaluated in the context of how nanocarrier based drug delivery systems of antitumor 
agents that depends on the EPR-effect will improve intratumoral accumulation and therapeutic 
efficacy relative to corresponding free drugs. Additionally, uptake and release kinetics must be 
appropriate relative to the drug delivered in order to achieve maximal efficacy. Based on these 
considerations tumor targeted nanocarrier drug delivery systems may prove to have very different 
efficacy for different tumors and could potentially decrease the therapeutic efficacy relative to the 
free-agent in some instances.28 The liposome formulation under investigation is the same as used in 
the marketed formulation Doxil with respect to liposome size and lipid composition but does not 
have the elongated shape as Doxil. The data reported on tumor uptake and intratumoral 
heterogeneity is therefore expected to be representative for long-circulating liposome formulations 
and potentially also a number of other PEGylated nanocarriers in the same size range.  
Radiolabeled liposomes have previously been evaluated in human cancer patients.15-18 The tumor 
accumulation levels of [Cu-64]-liposomes in the included carcinomas that displayed EPR effects 
(based on increasing accumulation between scans) are compatible to those reported in previous 
human cancers evaluated by gamma camera and SPECT imaging.15 The authors report tumor uptake 
from tumor size estimations to range from 2.7 – 53.0 %ID/kg. Tumor uptake was found to decrease 
with increasing tumor size and highest uptake was observed in head and neck squamous cell 
carcinoma (SCC), intermediate uptake in lung cancers and lowest in breast cancers.15 However, 
these reports in human cancers have only provided semi-quantitative estimation of liposome 
biodistribution based on single photon imaging at a single time-point, which, considering 
circulation times and tumor blood volume, limits the evaluation of the EPR-effect. Due to the high 
detection sensitivity and spatial resolution and the true quantitative nature of PET we can report 
accurate 3D quantitative measurements of [Cu-64]-liposome distribution after a shorter distribution 
period. Tumor-to-blood ratios are therefore reported at 1 h and 24 h after liposome infusion. This 
analysis clearly demonstrates the EPR-effect, as the tumor-to-blood ratio will increase if the 
nanocarriers extravasate into the interstitial space in the tumor. The EPR-effect was found to be 
present only in the carcinomas, except one mammary adenocarcinoma, as derived from the 
increased uptake level and retention of liposomes after a distribution period of 24 h (evaluated by 
tumor-to-blood ratios). The small SCC of dog 1 displayed the largest increase in %ID/kg and 
tumor-to-muscle ratio between 1 h and 24 h of distribution, which is in accordance with previous 
reports.15,29 The study by Harrington et al.15 reports four of five breast cancers as positive (visible) 
on both planar gamma camera and SPECT imaging after 72 h. However, activity levels of 
radiolabeled liposomes in at least two, but potentially 3 out of 4, of the positive breast cancers are 
comparable to those observed in the present study after only 1 h of liposome distribution and it may 
therefore be more reflective of tumor blood volume. This observation questions whether positive 
images always reflect the EPR-effect and underlines that a minimum of two scanning time points 
may be needed to identify the EPR-effect by imaging. Due to the limited number of studies and the 
potential poor correlation between tumor visualization by imaging and the presence of the EPR-
effect in tumors, further studies are warranted in humans to clarify which tumor types that can 
benefit the most from nanocarrier based therapeutics. 
The observed intratumoral heterogeneity in liposome accumulation underlines the importance of 
further elucidation of liposome accumulation and drug release. To what extent this is influenced by 
hypoxic regions, interstitial fluid pressure and regional differences in vasoactive factors or how it 
will influence distribution of liposomes functionalized with ligands that target tumor specific 
receptors is not clear and studies are required to identify the interdependence of these parameters. 
This study therefore, in addition to providing new information on EPR-based tumor accumulation 
and heterogeneity, also highlights the importance of further elucidating the drug distribution of 
liposome-encapsulated drug following their release. These issues may be a potential Achilles heel 
for nanocarrier based drug delivery systems as cancer cells with known therapeutic resistance, 
including hypoxic cells and cancer stem cells, may reside in perinecrotic and/or hypoxic regions 
and niches displaying low accumulation of nanocarriers. When evaluating the histograms and 
activity levels of this study the resolution of the PET scan and reconstruction algorithm must be 
taken into consideration as each voxel represent a large number of cancer cells and a small, 
potentially heterogeneous, tumor sub-volume. The histograms therefore provide information on the 
liposome concentrations that can be achieved within solid tumors, which again must be compared to 
studies of drug release kinetics and diffusion and distribution of released free anti-tumor agents. 
The accumulation level (%ID) that was achieved in the tumors in this study, relative to those 
reported for experimental models, may if translated directly, seem disappointing. However, we have 
previously reported tumor accumulation levels of passively accumulating radiolabeled liposomes to 
range from 4.8 to 6.0 %ID/cm3 between 24 and 48 h after injection in different xenograft models.24,30 
However, if considering that the tumors of the experimental animal models represented between 2 – 
5% of the total bodyweight and applying a similar relationship between tumor and host compatible 
for the carcinomas of the present dog study similar numbers are achieved based on %ID/cm3. The 
evaluation of liposomal accumulation in experimental rodent models must therefore be carefully 
interpreted when investigating the potential for imaging and drug delivery systems.  
Based on the findings in the present study, EPR-based passive accumulation of PEGylated 
liposomes (or other nanocarriers) in the 100 nm size-range cannot be considered a universal feature 
of all solid tumors. In this study, the SCC tumor had the highest EPR-effect and it is noteworthy 
that the majority of tumors included in the Harrington et al.15 study also were SCC tumors. 
Different approaches are currently being investigated to improve and increase the EPR-effect, 
including downsizing of nanoparticles and manipulation of tumor microenvironment,10,31 which 
could generate important information that could expand the tumor types where nanocarriers will be 
effective. Another approach has been to specifically trigger drug release from nanocarriers within 
the tumor vasculature to improve drug distribution in tumor.32 Furthermore, the influence of 
cytotoxic agents, anti-angiogenic drugs and radiotherapy must be investigated; to identify their 
impact on EPR-based drug delivery. Importantly, the optimization of drug delivery may become 
central in cancer therapy when considering the growing skepticism towards the possibilities and 
perspectives for individualized targeted therapy,33 making tumor specific and dose escalating 
delivery of chemotherapeutic agents an attractive methodology to overcome resistance and improve 
treatment outcome.   
 
Conclusion  
In the present article we have presented a new and highly efficient method for loading copper-64 
PET isotopes into liposomes without the use of ionophores based on a highly surprising diffusion of 
copper ions across liposome membranes where it is then entrapped by a high affinity copper 
chelator. This new loading method will be highly valuable in future PET studies with liposomes in 
animals and patients. Furthermore, even with the moderate number of 11 canine cancer patients and 
different histologies included, which is a consequence of the logistics of using family owned canine 
patients, this study identifies several highly important issues for nanocarrier based drug delivery to 
spontaneous tumors, including tumor type dependent differences and accumulation heterogeneity.  
Moderate to high nanocarrier tumor accumulation levels were achieved in spontaneous carcinomas 
based on the EPR-effect, which underlines the potential of nanocarrier drug delivery systems for 
elevating drug concentrations specifically within certain tumors. However, heterogeneity in 
intratumoral liposome distribution and drug release in the extracellular matrix may prove to be very 
important issues for optimization of liposomal drug delivery to achieve high therapeutic efficacy. 
Importantly, based on our observations, studies of specific malignancies and potentially even 
tumors of individual patients are needed to identify patients that are likely to benefit from 
nanocarrier based drug delivery. Radiolabeled liposomes may therefore serve as theranostic 
imaging agent guiding both diagnostic and therapeutic intervention for several malignancies in 
future clinical practice and guide patient selection for optimized clinical trails. 
 
Materials and Methods 
Study population. Canine cancer patients suffering from solid malignant tumors were eligible 
for inclusion. All dogs underwent clinical examination and had blood biochemical, hematological 
and urine analysis performed in preparation for anesthesia and to identify concurrent illnesses. 
Owners of included dogs provided written informed consent prior to inclusion. Eleven dogs met the 
inclusion criteria; 5 soft tissue sarcomas, 6 carcinomas (Table 1). The study protocol was approved 
by the ethical and administrative committee at the Department of Small Animal Clinical Sciences, 
University of Copenhagen, Denmark.  
 
Liposome formulation and production - Materials. Freeze-dried lipid mixture, hydrogenated soy 
phosphatidylcholine (HSPC)/cholesterol (Chol)/1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[methoxy (polyethylene glycol)-2000] (DSPE-PEG2000) in the molar ratio (56.5:38.2:5.3) was 
purchased from Lipoid®GmbH (Ludwigshafen, Germany). 1,4,7,10-tetra-azacyclododecane-
1,4,7,10-tetraacetic acid (DOTA) was purchased from Macrocyclics (Dallas, USA). All other 
solvents and chemicals were purchased from Sigma Aldrich (Schnelldorf, Germany) and were used 
without further purification. 10 ml LIPEX Thermobarrel Extruder and polycarbonate membranes 
were purchased from Northern Lipids (Burnaby, Canada) and the Minimate™ tangential flow 
filtration system was purchased from Pall Corporation (Canada). 
 
Preparation of DOTA-liposomes and Empty-liposomes. Freeze-dried Lipoid® lipid mixture: 
HSPC/Chol/DSPE-PEG2000 in the molar ratio (56.5:38.2:5.3) was hydrated with a HEPES buffer (10 
mM, 150 mM NaCl, pH 7.4) containing DOTA (CDOTA = 10 mM) adjusted to pH 7.4 and 335 
mOsm/l, and subsequently placed on a heating block with stirring at 65°C for 80 min. The hydrated 
solution was then extruded through polycarbonate membranes with pore sizes of 100 nm to 
generate 100 nm sized liposomes using a 10 ml LIPEX Thermobarrel Extruder placed on a heating 
block at 65°C during the extrusion process. The extruded 100 nm liposome-solution was then 
transferred to a Minimate™ tangential flow filtration system to remove un-encapsulated DOTA on 
the outside of the liposomes. The external buffer solution containing DOTA was replaced with a 
HEPES buffer (10 mM, 150 mM NaCl, pH 7.4, 295 mOsm/l). The purified DOTA-containing 
liposomes were then loaded with [Cu-64] (as described below) before in vivo administration. 
Empty-liposomes consisting of freeze-dried Lipoid® lipid mixture: HSPC/Chol/DSPE-PEG2000 in 
the molar ratio (56.5:38.2:5.3) were prepared as follow. The lipids were dispersed by adding an 
aqueous solution, a HEPES buffer (10 mM, 150 mM NaCl, pH 7.4, 295 mOsm/L). The solution 
was then hydrated at 65°C for 60 min followed by extrusion through polycarbonate membranes to 
generate 100 nm sized liposomes using a 10 ml LIPEX Thermobarrel Extruder.  
The size and zeta-potential of both DOTA-liposomes and Empty-liposomes were monitored 
using dynamic light scattering (ZetaPALS, Brookhaven Instruments, US) over the period where 
dogs were enrolled in the study, which yielded an average diameter of 110 nm ± 5 nm (PDI < 
0.075) and an average zeta-potential of -7 mV± 3 mV. The lipid/phosphorus concentration was 
verified by measurement of phosphorus concentration using ICP-MS (iCAP Q, Thermo Scientific, 
DE) using Gallium as internal standard. 
 
[Cu-64] production. Copper-64 was produced on a PETtrace cyclotron (GE Healthcare) 
equipped with a beamline. The production of [Cu-64] was carried out via the 64Ni(p,n)64Cu nuclear 
reaction using a solid target system consisting of a water cooled target mounted on the beamline. 
The target consisted of [Ni-64] metal (enriched to >99%) electroplated on a silver disc backing. A 
proton beam of 16 MeV and a beam current of 20 mA were used. After irradiation, the target was 
transferred to the laboratory for further chemical processing where [Cu-64] was isolated using ion 
exchange chromatography. Final evaporation from aqueous HCl yielded [Cu-64] as [Cu-64]Cl2. 
 
[Cu-64] labeled liposomes. Purified DOTA-containing liposomes were added to the vial 
containing the radioactive [Cu-64]Cl2 followed by incubation at 50-55°C for 60 min. The fraction 
of un-entrapped [Cu-64]-DOTA in the loaded [Cu-64]-liposome solution was quantified by 
separating [Cu-64]-DOTA from [Cu-64]-liposomes by size exclusion chromatography using a 
Sephadex G-50 column (1x25 cm) eluted with a HEPES buffer (10 mM, 150 mM NaCl, pH 7.4). 
The fraction of un-entrapped free [Cu-64] in the [Cu-64]-liposome solution was quantified by 
separating un-entrapped [Cu-64] from [Cu-64]-DOTA by radio-thin layer chromatography (radio-
TLC). The radiochemical purity of the produced radiolabeled [Cu-64]-liposomes was >95% in all 
productions used in this study.  Before infusion, Empty-liposomes (4.3 mg lipid/kg canine) were 
added to the [Cu-64]-liposomes solution to ensure injection of a sufficient amount of liposomes to 
make them long circulating. 
 
PET/CT. PET/CT scans were performed using a combined PET/CT scanner (Biograph 40 
PET/CT or Biograph 64 PET/CT, Siemens, Erlangen, Germany); consisting of a high resolution 
PET scanner (4 x 4 mm LSO crystal elements, 32,440 LSO crystals, 21.6 cm axial field) and a 40 or 
64-row multi-slice CT scanner. CT parameters used were a slice thickness of 3.0 mm, 120 kV, 170 
mAs, pitch 1.2, collimation 24 x 1.2 mm and a B30 kernel. The PET scans were acquired using 
static image acquisition and dynamic list mode acquisition. Images were reconstructed using a 3D 
acquisition mode and attenuation corrected using the concurrent CT scan. PET images were 
reconstructed using TrueX® (Siemens, Erlangen, Germany) 3D reconstruction (21 iterations, 3 
subsets), and smoothed using a Gaussian filter having a FWHM of 2 mm in all directions, and a 
matrix size of 336 x 336. 
 
Study procedure FDG PET/CT (day 1). The dogs were fasted for a minimum of 12 h prior to 
imaging and all were confirmed to have normal serum glucose concentrations. Dogs were pre-
medicated with Methadone (0.2 to 0.3 mg/kg IM). FDG was injected intravenously as a bolus. Dogs 
received a mean FDG activity of 7.0 MBq/kg (range: 3.8-9.85 MBq/kg). 
All dogs were visually monitored after FDG administration. Following a distribution period for 
the tracer (mean 61 min (range: 56-67 min)), anaesthesia was performed using a continuous 
infusion of propofol (15-25 mg/kg/h), and provided with 100% oxygen via a tracheal tube. FDG 
PET/CT scans were performed as a 3-minute multi field of view (FOV) whole body PET scan.  
 
Study procedure [Cu-64]-liposome PET/CT (day 2 and 3). [Cu-64]-liposome PET scans were 
performed as two separate scanning session commencing between 24 and 48 h after the FDG 
PET/CT scan. The first [Cu-64]-liposome scan was initiated simultaneously with the infusion of 
radiolabeled liposomes (termed day 1-hour scan) and the second liposome scan was performed 
approximately 24 h after (termed day 24-hour scan). Anesthesia was conducted as for the FDG 
PET/CT scan and all dogs received 2 mg/kg dexamethasone disodium phosphate ~2 h prior to 
infusion of [Cu-64]-liposomes to minimize risks for immunogenic reactions. Radiolabeled 
liposomes were infused at increasing rates over a period of 20 min using an automated injection 
pump. Infusion rates were; 0.5 ml/min (0-5 min), 1.0 ml/min (5-10 min), 2.5 ml/min (10-15 min) 
and 4 ml/min (15-20 min) for a total infusion volume of 40 ml. Dogs received a mean [Cu-64]-
liposomal activity of ~10 MBq/kg.  
The 1-hour [Cu-64]-liposome PET/CT scan was performed as a dynamic list mode acquisition. 
In dogs 1 to 6 the PET scanner FOV was positioned to cover the liver and spleen region for the 
initial 0-40 min. After 40 min the PET scanner FOV was moved to the tumor region for a 20-
minute dynamic list mode acquisition. Dynamic list mode data were temporally reconstructed into 
images at 1 min intervals and the list mode data from the tumor region was additionally 
reconstructed into a summarized 5-minute image based on 55-60 min list mode data. The tumor of 
dog 2 could not be covered by a single FOV and an additional static 2.5-minute FOV scan was 
performed to cover the entire tumor volume and these images served as the basis for determining 
tumor uptake values at the 1-hour scans.   
The 24-hour [Cu-64]-liposome PET/CT scan was initiated by a static 5 min FOV acquisition in 
the tumor region followed by a 2.5 min FOV whole body PET scan. [Cu-64]-liposome PET/CT 
scan were reconstructed using the same TrueX® reconstruction algorithm and parameters as for the 
FDG PET scans and attenuation corrected using the concurrently acquired CT scan. 
 
Image analysis. Attenuation corrected and reconstructed PET/CT images were post processed 
using commercial software (Pmod, ver. 3.304, Pmod Technologies, Switzerland).  
Tumor volumes of interests (VOIs) were manually delineated on the FDG PET/CT and [Cu-64]-
liposome PET/CT scans, without applying any threshold for the PET uptake following the different 
malignancies being evaluated. FDG uptake was reported as tumor mean and maximum standardized 
uptake value (SUV). Tumor uptake of [Cu-64]-liposome on the 1-hour (5-minute reconstruction, 
55-60 min list mode data) and 24-hour tumor scans were reported as tumor mean and maximum 
SUV and 24-hour scan voxel uptake histogram constructed. Tumor uptake percentage of injected 
dose (%ID) was calculated for the whole tumor and for voxel mean and maximum. Intratumoral 
heterogeneity of liposome accumulation was investigated by constructing voxel uptake histograms 
of tumor VOIs based on the 24-hour PET images.  
Pulmonary and lymph node metastases were identified and delineated in dog 2, the uptake levels 
of FDG and [Cu-64]-liposome are reported as for the primary tumors.  
PET time activity curves (PET-TAC) for blood, liver and spleen were generated from the 1-hour 
scan on temporally reconstructed images. Blood activity was determined by generating a large VOI 
around the aorta and subsequently segmenting the VOI by an 80% of maximum threshold to 
minimize partial volume effects and non-blood associated activity. VOIs manually drawn well 
within the margins of liver and spleen on five consecutive image slices were used for the 
determination of temporal activity. PET Blood activity for the determination of tumor to blood 
ratios at the 1-hour PET scan was estimated by decay correcting average blood activity 38-40 min 
post-injection (pi) to the 1-hour time point of tumor activity. For technical reasons TAC curves 
were not constructed for dogs 9 and 10. 
[Cu-64]-liposome biodistribution and tumor to reference tissue uptake ratios at the 24-hour 
whole body PET scan 24 h after liposome infusion were evaluated by constructing reference VOIs 
in the following tissues; aorta, liver, spleen, muscle (average of five regions), lung (peripheral 
region), bone marrow (proximal humerus, representing red bone marrow), ventricular septum, 
parotid salivary glands, urinary bladder and gall bladder. All regions were drawn well within the 
margins of tissues and organs and excluding regions containing larger blood vessels, e.g. the hilar 
region of the liver, to avoid artifacts and minimize partial volume effects and respiratory movement. 
Aorta VOIs were constructed as described above. Ventricular septum VOIs was formed by PET 
uptake based on segmentation to minimize the effects of blood activity in heart ventricles and heart 
movement during scanning. In short a spherical VOI including the right and left heart ventricles and 
ventricular septum was constructed and segmentation performed.  
 
Time activity curves (TACs). TACs were generated for the individual dogs by collecting 
multiple blood samples. Blood samples were collected as allowed for during and after the [Cu-64]-
liposome PET/CT scans without interfering with scanning procedures. Ten dogs had blood samples 
collected between 11 to 1509 min after completing the liposome infusion. EDTA stabilized blood 
samples were well counted (Gamma counter, Perkin Elmer, Australia) in triplicates and decay 
corrected specific blood activity of [Cu-64]-liposome calculated. The relative percentage of [Cu-
64]-liposome in circulation was estimated from an expected blood mass of 8% of total body weight 
and relative blood content plotted against distribution period. Circulating half-life of liposomes was 
calculated using the non-linear one-phase exponential decay equation: y = Ae-kt, t1/2 = 0.693/k.  
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Figure  S1. [Cu-64]-liposome PET/CT images (24 hours pi.) of dog 1 to 6 (numbering is identical to main 
text). Dog 1; intranasal squamous cell carcinoma, dog 2; mammary gland adenocarcinoma, dog 3; 
mandibular adenocarcinoma, dog 4; masticatory muscle soft tissue sarcoma, dog 5; neck musculature soft 
tissue sarcoma, dog 6; antebrachial liposarcoma. White arrows indicate tumors, red arrow indicate the spleen 
and yellow arrow the liver. The circulation time of [Cu-64]-liposomes in the blood can be appreciated by the 
high intravascular activity in larger blood vessels. For additional information on tumors, dogs and [Cu-64]-
liposome accumulation please refer to main text and Table 1 and 2. 
		
		
Figure  S2. [Cu-64]-liposome PET/CT images (24 hours pi.) of dog 7 to 11 (numbering is identical to main 
text). Dog 7; intranasal transitional cell carcinoma, dog 8; digital soft tissue sarcoma in the front paw, dog 9; 
mammary gland adenocarcinoma, dog 10; intranasal squamous cell carcinoma, dog 11; intranasal 
adenocarcinoma. White arrows indicate tumors, red arrow indicates the spleen. The circulation time of [Cu-
64]-liposomes in the blood can be appreciated by the high intravascular activity in larger blood vessels. For 
information on tumors, dogs and [Cu-64]-liposome accumulation please refer to main text and Table 1 and 2. 
 		 	
 
 
 
Figure S3. Histograms displaying voxel-wise uptake characteristics of %ID/kg [Cu-64]-liposome in tumor 
from included dogs. The white bars of dog 11 represents %ID/kg corrected for 50% free-[Cu-64]-DOTA and 
gray bars uncorrected uptake of 50% [Cu-64]-liposomes/50% [Cu-64]-DOTA.  
 
 	
Figure S4. Histograms displaying voxel-wise tumorvoxel-to-musclemean ratios [Cu-64]-liposome activity. The 
white bars represents voxels with a tumor-to-muscle ration below 1.5. For PET imaging a lesion-to-
background ratio above 1.5 is required for acceptable image contrast.	
		
Figure S5. A: PET/CT images of [64-Cu(aq)] (left), [Cu-64]-DOTA (middle) and [Cu-64]-liposomes (right) 
in mice. Top row; images acquired 1 hour after intravenous administration of 10-12 MBq (20 mg lipid/kg, 
encapsulation >95%). Bottom row; images acquired after a distribution period of 24 hours. B: Time activity 
curves (TAC) of dynamically acquired PET/CT displaying [Cu-64] activity in blood, liver and urinary 
bladder for [64-Cu(aq)] (red), [Cu-64]-DOTA (blue) and [64-Cu]-liposomes (black). Yellow arrows; heart, 
Red arrows; liver, Green arrows; spleen. The spleen could not be securely identified on the PET/CT scans of 
[Cu-64(aq)] and [Cu-64]-DOTA following poor image contrast. The blue arrow displays the high blood 
activity of [Cu-64]-liposomes in larger abdominal/pelvic vessels. The PET/CT images and TAC clearly 
displays the long circulating properties of [Cu-64]-liposomes compared to [Cu-64]-DOTA and [Cu-64(aq)]. 
The renal excretion of [Cu-64]-DOTA is extremely fast and very low urine activity levels of [Cu-64] are 
observed in mice injected with [Cu-64]-liposomes. Additionally, the mice injected with [Cu-64]-liposomes 
display a low and fast decreasing [Cu-64] activity in the bladder, which indicates that small amounts of un-
encapsulated [Cu-64]-DOTA is rapidly excreted and circulating liposomes are not leaking [Cu-64]-DOTA 
following the reduction in urine activity with continuing urine output (dilution). High hepatic uptake of free 
[Cu-64(aq)] is observed. This is expected following the high level of copper transporters in the liver. [Cu-
64]-liposomes displays an intermediate uptake compared to [Cu-64(aq)] and [Cu-64]-DOTA. The liver (red 
arrow) and spleen (green arrow) accumulation is compatible and indicate that [Cu-64]-liposomes are 
recognized by the retriculoendothelial systems (RES) and do not accumulate in the liver by a copper 
dependent transport mechanism.  
 		
	
Figure S6. In vitro stability test of liposomes loaded with 64Cu in dog plasma. Liposomes loaded with 500 
MBq 64Cu/ml was mixed with dog plasma in a 1:1 ratio, and incubated for 18h at 37°C. The liposome-
plasma mixture (200 µL) was separated on a size-exclusion column (Sephadex G50 fine, 25 x 1.5 cm) using 
a flow of 1ml/ml (green fractions), and fractions were collected every 2nd min. The 64Cu activity of the 
different fractions was measured using a calibrated high-purity germanium detector (Princeton, Gammatech). 
Each sample was placed in a distance of 20 cm measured from the surface of the detector crystal. Energy and 
efficiency calibrations were performed prior to measuring using certified sealed radioactive sources of 133Ba 
and 152Eu. The spectra were obtained and analyzed using Canberra Genie2K software. The 64Cu activity of 
each sample was determined by integration of the 511 keV annihilation peak and the activities were 
calculated based on the 20 cm efficiency calibration. [Cu-64]-DOTA was included as a control to determine 
retention-time of the free [Cu-64]-DOTA (blue fractions). The leakage of [Cu-64]-DOTA from the 
liposomes in dog plasma was <3% (𝑙𝑒𝑎𝑘𝑎𝑔𝑒 =  𝐴!"#$!!"!!!" / 𝐴!"#$!!"!!! , where 𝐴!"#$!  is the activity of the 
i’th fraction). The stability of liposomes loaded with 64Cu, was furthermore investigated in human and mice 
serum, and <5% and <2% leakage was found respectively. 
 
